rawfin.tv
TD Cowen Initiates Odyssey Therapeutics With Buy Rating
MarketsstocksAI Generated

TD Cowen Initiates Odyssey Therapeutics With Buy Rating

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

TD Cowen has begun coverage of Odyssey Therapeutics Inc., assigning a "Buy" rating to the biotechnology firm. This initiation follows a recent "Overweight" rating from another analyst, signaling growing positive sentiment.

Biotech StocksAnalyst RatingBuy RatingTD Cowen

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks